InvestorsObserver
Sign Up Login

SURF Surface Oncology Inc

$1.98 $0.00 (0.00%)
Add to Watchlist Compare
Overall

SURF Stock Analysis Overview

What this means: InvestorsObserver gives Surface Oncology Inc (SURF) an overall rank of 27, which is below average. Surface Oncology Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 27 means that 73% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

SURF Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

SURF Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

SURF Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

SURF Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

SURF Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

SURF Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

SURF Stock Analysis Overview

What this means: InvestorsObserver gives Surface Oncology Inc (SURF) an overall rank of 27, which is below average. Surface Oncology Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 27 means that 73% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full SURF report

SURF Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

SURF Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

SURF Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

SURF Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

SURF Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

SURF Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Surface Oncology Inc (SURF) Analyst Forecast

SURF Price, Volume, Earnings, and Dividend Date

  • Last Price $1.98
  • Previous Close $1.98
  • Change $0.00
  • Open $2.05
  • Volume 421,900
  • Avg. Volume (100-day) 693,664
  • Market Cap 79,014,011
  • Days Range 1.95 - 2.12
  • 52-week Range 1.86 - 9.57
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/07/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.625
  • PEG Ratio —

Surface Oncology Inc (SURF) Company Description

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out through the region of the United States.

Surface Oncology Inc (SURF) Stock Chart

View Interactive SURF chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Liquidia Corp (LQDA) (LQDA) $5.61
Veru Inc (VERU) (VERU) $15.01
Concert Pharmaceutic (CNCE) (CNCE) $4.79
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $19.50
Trevi Therapeutics Inc (TRVI) (TRVI) $2.24
Adma Biologics (ADMA) (ADMA) $2.01
Vaxcyte Inc (PCVX) (PCVX) $24.03
Fennec Pharmaceuticals Inc (FENC) (FENC) $5.97
Lyra Therapeutics Inc (LYRA) (LYRA) $5.61
Bellus Health Inc (BLU) (BLU) $8.80